Oligonucleotide Synthesis Market: Growth, Size, Share, and Trends
Report Code
BT 2680
Published in
Jun, 2025, By MarketsandMarkets™
Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic (Rare Diseases), Research, Diagnostics) - Global Forecast to 2030
USD 24.70 BN
MARKET SIZE, 2030
CAGR 18.6%
(2025-2030)
456
REPORT PAGES
568
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The oligonucleotide synthesis market is projected to reach USD 24.70 billion by 2030 from USD 10.50 billion in 2025 at a CAGR of 18.6% during the forecast period. The major factors driving the growth of this market include the increasing use of synthesized oligos for therapeutic & diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research and synthetic biolog, and the growing focus on precision/personalized medicine.
KEY TAKEAWAYS
-
BY REGIONThe North America oligonucleotide synthesis market dominated, with a share of 45.4% in 2024. The presence of several global players and the growing research activities for the development of oligonucleotide-based therapeutics, are some factors supporting the growth of the North American market.
-
BY PRODUCTSBy products, the oligonucleotide-based drugs segment accounted for the largest share of 66.8% of the market in 2024. This dominance can primarily be attributed to the increasing number of FDA-approved drugs and the growing clinical pipeline of oligonucleotide-based drugs.
-
BY APPLICATIONBy application, the therapeutic applications segment is expected to register the highest CAGR of 19.7%, owing to the increasing use of oligonucleotides as therapeutic agents, such as antisense oligos (ASOs) and siRNAs, for treating neurological & rare diseases.
-
BY END USERBy end user, the hospitals segment is expected to grow at the fastest rate, owing to the increasing FDA approvals for oligonucleotide-based drugs, increasing awareness about alternative therapies and the growing investments in healthcare spending.
-
COMPETITIVE LANDSCAPEMajor players in the global oligonucleotide synthesis market, such as Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, among others have employed various strategies to expand their global footprints and increase their market shares such as product launches, expansions, acquisitions, partnerships, and collaborations.
The oligonucleotide synthesis market is witnessing steady growth, propelled by rising demand for therapeutic oligos (siRNA, ASO, mRNA adapters, CRISPR guides) and clinical-grade GMP manufacturing. Growth is also driven by routine use in qPCR/NGS library prep, companion diagnostics, and synthetic biology (gene circuits, DNA data storage, pooled screens). Buyers prioritize fast turnaround, high purity, and scalable QC (HPLC/UPLC, LC–MS) as programs move from research to IND/BLA.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
While customer demand in the broader healthcare landscape is shifting from traditional chemical-based therapies to advanced biotechnology-based treatments, this evolution creates new revenue opportunities for players in the oligonucleotide synthesis market. Emerging therapeutic areas such as genetic disorders, rare diseases, oncolog, urology, infectious diseases, neurology, and cardiovascular diseases drive demand for oligonucleotide-based solutions. Additionally, adjacent markets—including gene therapy, metagenomic sequencing, biosimilars, therapeutic vaccines, peptides and therapeutic proteins, and RNA therapeutics—are opening as lucrative avenues for growth.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Increasing use of synthesized oligos in therapeutic & diagnostic applications
-
Growing government investments in life science research and synthetic biology
RESTRAINTS
Impact
Level
Level
-
Complexities associated with therapeutic oligonucleotides
OPPORTUNITIES
Impact
Level
Level
-
Increasing R&D investments by key players in emerging economies
CHALLENGES
Impact
Level
Level
-
Lack of standard regulations
-
Delivery of oligonucleotide drugs to specific targets
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing use of synthesized oligos in therapeutic & diagnostic applications
The key driver of the rapid growth in the oligonucleotide market is the increasing potential for oligonucleotide-based drugs to treat a wide range of neurological disorders and orphan diseases. The rising regulatory approvals for these emerging therapies underscore their proven safety and effectiveness, boosting market confidence. A robust clinical pipeline further enhances the prospects for ongoing improvements and the launch of new products. Beyond therapeutic uses, oligonucleotides play a crucial role in applications such as microarrays, molecular diagnostics, genetic testing, and gene therapy, showcasing their versatility.
Restraint: Complexities associated with therapeutic oligonucleotides
One of the challenges in oligonucleotide synthesis is maintaining precise control over the length and structure of the therapeutic oligonucleotides while minimizing impurities. The process requires high precision and uniformity to meet the rigorous quality standards of regulatory authorities. However, these challenges become significantly more complex as the size and intricacy of the oligonucleotides increase. Another critical issue is the large amount of waste generated during the synthesis process. Many of the nucleotides used are not incorporated into the final target sequences, resulting in wasted materials. This creates harmful chemical waste, posing environmental concerns and increasing production costs.
Opportunity: Increasing R&D investments by key players in emerging economies
China, India, Japan, Brazil, and Argentina present significant growth opportunities for the oligonucleotide synthesis market. This growth is driven by increasing interest in biotechnology, the development of healthcare infrastructure in these countries, and substantial investments in research and development from major pharmaceutical and biotechnology companies. The Latin America and Asia Pacific regions are lucrative growth opportunities for global players aiming to expand market presence.
Challenge: Delivery of oligonucleotide drugs to specific targets
One of the significant challenges in delivering oligonucleotide-based medications is the inefficiency associated with conventional methods, particularly intravenous (IV) delivery. This inefficiency makes it challenging to administer antisense oligonucleotide (ASO)--based drugs in sufficient quantities to target tissues, compromising treatment effectiveness and potentially leading to unpredictable clinical responses. Another significant obstacle comes from the physicochemical properties of the oligonucleotides themselves. Due to their large size and negative charge, these molecules struggle to cross biological barriers, such as the blood-brain barrier (BBB).
oligonucleotide-synthesis-market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Used pooled synthetic oligonucleotide libraries (Twist Oligo Pools) to encode large, diverse protein-sequence sets for high-throughput folding/function screens. | Enabled rapid construction of thousands of designs| Reduced false positives from in-silico models | Experimental feedback improved computational tools. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The oligonucleotide synthesis market operates within a multi-tiered ecosystem spanning raw-material suppliers, oligonucleotide manufacturers, end users, and regulatory bodies. At the base are equipment, reagents, and consumables manufacturers, whose instruments and proprietary chemistries enable high-precision strand assembly. Upstream, pharmaceutical & biotechnology companies, academic and research institutes, and contract research and development organizations translate these capabilities into next-generation therapeutics. Hospitals and diagnostic centers are critical end users, validating safety and efficacy in diverse patient populations. Oversight by regulatory authorities ensures that each component of this tightly interconnected value chain meets rigorous quality, safety, and performance standards.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Oligonucleotide Synthesis Market, By Product
In 2024, the oligonucleotide-based drugs segment held the largest share of the market. This segment is also expected to be the fastest-growing segment in the market. The major factors driving the growth of this segment are the increasing number of regulatory approvals received for oligonucleotide-based drugs, increasing research focus on the development of oligonucleotide-based drugs, and a shifting focus on developing innovator oligonucleotide-based drugs against common indications such as cardiovascular diseases.
Oligonucleotide Synthesis Market, By Application
In 2024, the therapeutic applications segment held the largest share of the market. Oligonucleotide-based therapies are increasingly used treatment for rare diseases. These therapies consist of shott sequences of DNA or RNA that are highly specific and have a strong affinity for target molecules. By modifying the expression of genes involved in various disease pathways, these therapies offer a promising solution for treating diseases, including cancer, asthma, and diabetes.
Oligonucleotide Synthesis Market, By Product
The hospitals segment accounted for the largest share of the oligonucleotide synthesis market in 2024. The demand for oligonucleotide drugs in hospitals is due to the large number of patients seeking treatment for various conditions. These drugs are used to treat patients suffering from diseases such as Transthyretin Amyloidosis (ATTR), Duchenne Muscular Dystrophy (DMD), Spinal Muscular Atrophy (SMA), and Hepatic Veno-occlusive Disease (VOD).
REGION
North America to be fastest-growing region in global oligonucleotide synthesis market during forecast period
The North America oligonucleotide synthesis market is expected to register the highest CAGR during the forecast period, driven by significant investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. This has led to continuous advancements in oligonucleotide therapies. The early adoption of emerging technologies and alternative therapies, backed by a strong venture capital ecosystem, supports market growth.
oligonucleotide-synthesis-market: COMPANY EVALUATION MATRIX
In the oligonucleotide synthesis market matrix, Danaher Corporation (Star) leads with its broad DNA/RNA portfolio from research to GMP-grade supply, global footprint, and integration with Danaher’s automation/analytics deliver scale, quality, and fast turnaround across diagnostics, therapeutics, and synthetic biology. Maravai LifeSciences (Emerging Leader) rapidly expanding GMP oligo and modified-nucleotide capacity, leveraging CleanCap mRNA technology and CDMO services; as clinical oligo and mRNA/siRNA programs grow, Maravai is well positioned to advance toward the leaders’ quadrant.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Danaher Corporation (US)
- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Eurofins Scientific (Luxembourg)
- AstraZeneca (UK)
- Nippon Shinyaku, Co. Ltd. (Japan)
- Jazz Pharmaceuticals plc (Ireland)
- BIOCOMMA LIMITED (China)
- LGC Limited (UK)
- Agilent Technologies, Inc. (US)
- Kaneka Corporation (Japan)
- Maravai LifeSciences (US)
- Alnylam Pharmaceuticals, Inc. (US)
- Ionis Pharmaceuticals, Inc. (US)
- Novartis AG (Switzerland)
- Creative Biogene (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 8.87 Billion |
| Market Forecast in 2030 (Value) | USD 24.70 Billion |
| Growth Rate | CAGR of 18.6% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
WHAT IS IN IT FOR YOU: oligonucleotide-synthesis-market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Competitive Benchmarking of Key Players | Comparative profiling of major market participants covering business overview, product portfolios, pricing strategies, technological capabilities, and regional presence. | Provides insights on competitor positioning and supports differentiation strategies. |
| End-user Mapping and Opportunity Assessment | Identification and profiling of key end users including pharmaceutical & biotech companies, academic institutes, and CROs across high-growth regions. | Aids in customer targeting, partnership identification, and business expansion planning. |
RECENT DEVELOPMENTS
- July 2025 : AstraZeneca plans to invest USD 50 billion in the U.S. by 2030 to expand medicines R&D and manufacturing, including a new large drug-substance facility in Virginia that will produce small molecules, peptides, and oligonucleotides.
- February 2025 : Astellas Pharma Inc. (Japan) announced that the US FDA approved expanded US Prescribing information for IZERVAY for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a result, IZERVAY was approved without limiting the duration of dosing.
- February 2025 : Biogen (US) and Stoke Therapeutics (US) announced a collaboration for the development and commercialization of zorevunersen, an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene for the treatment of Dravet syndrome.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
43
2
RESEARCH METHODOLOGY
48
3
EXECUTIVE SUMMARY
61
4
PREMIUM INSIGHTS
64
5
MARKET OVERVIEW
Booming oligonucleotide market driven by technological advancements and rising R&D investments in emerging economies.
67
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
INCREASING USE OF SYNTHESIZED OLIGOS IN THERAPEUTIC & DIAGNOSTIC APPLICATIONS
5.2.1.2
TECHNOLOGICAL ADVANCEMENTS
5.2.1.3
GROWING GOVERNMENT INVESTMENTS IN LIFE SCIENCE RESEARCH & SYNTHETIC BIOLOGY
5.2.1.4
GROWING FOCUS ON PRECISION/PERSONALIZED MEDICINE
5.2.2
RESTRAINTS
5.2.2.1
COMPLEXITIES ASSOCIATED WITH THERAPEUTIC OLIGONUCLEOTIDES
5.2.3
OPPORTUNITIES
5.2.3.1
INCREASING R&D INVESTMENTS BY KEY PLAYERS IN EMERGING ECONOMIES
5.2.4
CHALLENGES
5.2.4.1
LACK OF STANDARD REGULATIONS
5.2.4.2
DELIVERY OF OLIGONUCLEOTIDE DRUGS TO SPECIFIC TARGETS
5.3
INDUSTRY TRENDS
5.3.1
GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
5.3.2
GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
5.3.3
FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
5.3.4
GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES
5.4
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5
VALUE CHAIN ANALYSIS
5.6
ECOSYSTEM ANALYSIS
5.6.1
ROLE IN ECOSYSTEM
5.7
TECHNOLOGY ANALYSIS
5.7.1
KEY TECHNOLOGIES
5.7.1.1
SOLID-PHASE SYNTHESIS
5.7.1.2
LIQUID-PHASE SYNTHESIS
5.7.1.3
ENZYMATIC OLIGO SYNTHESIS
5.7.2
COMPLEMENTARY TECHNOLOGIES
5.7.2.1
POLYMERASE CHAIN REACTION (PCR)
5.7.2.2
NEXT-GENERATION SEQUENCING
5.7.2.3
MICROARRAY ANALYSIS
5.7.3
ADJACENT TECHNOLOGIES
5.7.3.1
CRISPR
5.7.3.2
LIPID NANOPARTICLES
5.8
PRICING ANALYSIS
5.8.1
AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024
5.8.2
AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022−2024
5.8.3
AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022−2024
5.8.4
AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
5.8.5
AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024
5.8.6
AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
5.9
PATENT ANALYSIS
5.9.1
PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
5.10
PIPELINE ANALYSIS
5.11
TRADE ANALYSIS
5.11.1
IMPORT DATA (HS CODE 293499)
5.11.2
EXPORT DATA (HS CODE 293499)
5.12
KEY CONFERENCES & EVENTS, 2025–2026
5.13
TARIFF & REGULATORY LANDSCAPE
5.13.1
TARIFF DATA (HS CODE 2934.99, 3822.00)
5.13.1.1
TRADE POLICY UPDATES AFFECTING OLIGONUCLEOTIDE SYNTHESIS MARKET, 2022−2025
5.13.1.2
IMPACT OF TARIFFS ON PRICING & SUPPLY CHAIN
5.13.2
REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.13.3
REGULATORY FRAMEWORK
5.14
PORTER’S FIVE FORCES ANALYSIS
5.14.1
DEGREE OF COMPETITION
5.14.2
BARGAINING POWER OF SUPPLIERS
5.14.3
BARGAINING POWER OF BUYERS
5.14.4
THREAT OF SUBSTITUTES
5.14.5
THREAT OF NEW ENTRANTS
5.15
KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2
BUYING CRITERIA FOR END USERS
5.16
CASE STUDY ANALYSIS
5.16.1
CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
5.16.2
CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
5.16.3
CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
5.17
INVESTMENT/FUNDING SCENARIO
5.18
IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
5.19
TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET
5.19.1
KEY TARIFF RATES
5.19.2
PRICE IMPACT ANALYSIS
5.19.3
KEY IMPACT ON VARIOUS REGIONS
5.19.3.1
US
5.19.3.2
EUROPE
5.19.3.3
APAC
5.19.3.4
REST OF THE WORLD
5.19.4
END-USE INDUSTRY IMPACT
5.19.4.1
HOSPITALS
5.19.4.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
5.19.4.3
DIAGNOSTIC LABORATORIES
5.19.4.4
CROS & CDMOS
5.19.4.5
ACADEMIC & RESEARCH INSTITUTES
6
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 106 Data Tables
124
6.1
INTRODUCTION
6.2
OLIGONUCLEOTIDE-BASED DRUGS
6.2.1
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
6.2.1.1
ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
6.2.1.2
SIRNA OLIGONUCLEOTIDE-BASED DRUGS
6.2.1.3
OTHER OLIGONUCLEOTIDE-BASED DRUGS
6.3
SYNTHESIZED OLIGONUCLEOTIDES
6.3.1
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
6.3.1.1
PRIMERS
6.3.1.2
PROBES
6.3.1.3
DNA OLIGONUCLEOTIDES
6.3.1.4
RNA OLIGONUCLEOTIDES
6.3.1.5
OTHER SYNTHESIZED OLIGONUCLEOTIDES
6.3.2
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
6.3.2.1
CUSTOM OLIGONUCLEOTIDES
6.3.2.2
PREDESIGNED OLIGONUCLEOTIDES
6.4
REAGENTS & CONSUMABLES
6.4.1
GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
6.5
EQUIPMENT
6.5.1
TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET
7
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 66 Data Tables
174
7.1
INTRODUCTION
7.2
THERAPEUTIC APPLICATIONS
7.2.1
THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
7.2.1.1
NEUROLOGICAL DISORDERS
7.2.1.2
RARE DISEASES
7.2.1.3
OTHER DISEASES
7.3
RESEARCH APPLICATIONS
7.3.1
PCR
7.3.1.1
INCREASING USE OF PCR IN MOLECULAR BIOLOGY RESEARCH TO DRIVE MARKET
7.3.2
SEQUENCING
7.3.2.1
ADVANCEMENTS IN SEQUENCING TECHNOLOGIES & LOW COST OF DNA SEQUENCING TO BOOST MARKET
7.3.3
OTHER RESEARCH APPLICATIONS
7.4
DIAGNOSTIC APPLICATIONS
7.4.1
INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH
8
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 36 Data Tables
205
8.1
INTRODUCTION
8.2
HOSPITALS
8.2.1
INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET
8.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.3.1
GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET
8.4
DIAGNOSTIC LABORATORIES
8.4.1
RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL MARKET
8.5
CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
8.5.1
WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT MARKET GROWTH
8.6
ACADEMIC RESEARCH INSTITUTES
8.6.1
GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET
9
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 19 Countries | 239 Data Tables.
224
9.1
INTRODUCTION
9.2
NORTH AMERICA
9.2.1
NORTH AMERICA: MACROECONOMIC OUTLOOK
9.2.2
US
9.2.2.1
GOVERNMENT INITIATIVES AND STRATEGIC DEVELOPMENTS BY LEADING PLAYERS TO DRIVE MARKET
9.2.3
CANADA
9.2.3.1
STRONG RESEARCH INFRASTRUCTURE AND AVAILABILITY OF FUNDING TO SUPPORT MARKET GROWTH
9.3
EUROPE
9.3.1
EUROPE: MACROECONOMIC OUTLOOK
9.3.2
GERMANY
9.3.2.1
GOVERNMENT & PRIVATE FUNDING INVESTMENTS TOWARDS HEALTH RESEARCH TO DRIVE MARKET
9.3.3
UK
9.3.3.1
STRATEGIC COLLABORATIONS & PARTNERSHIPS BETWEEN KEY MARKET PLAYERS TO FUEL MARKET
9.3.4
FRANCE
9.3.4.1
FAVORABLE GOVERNMENT INITIATIVES FOR GENOMICS RESEARCH TO BOOST DEMAND
9.3.5
ITALY
9.3.5.1
INCREASING R&D EXPENDITURE FOR PHARMA & BIOTECH COMPANIES TO SUPPORT MARKET GROWTH
9.3.6
SPAIN
9.3.6.1
FAVORABLE FUNDING INVESTMENTS FOR BIOMEDICAL RESEARCH TO DRIVE MARKET
9.3.7
REST OF EUROPE
9.4
ASIA PACIFIC
9.4.1
ASIA PACIFIC: MACROECONOMIC OUTLOOK
9.4.2
CHINA
9.4.2.1
EXPANSION OF LEADING PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
9.4.3
JAPAN
9.4.3.1
GROWING RESEARCH INITIATIVES & STRATEGIC DEVELOPMENTS TO BOOST DEMAND
9.4.4
INDIA
9.4.4.1
DEVELOPMENT OF BIOCLUSTERS AND IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
9.4.5
AUSTRALIA
9.4.5.1
INCREASING GOVERNMENT INITIATIVES AND RESEARCH FUNDING TO SUPPORT MARKET GROWTH
9.4.6
SOUTH KOREA
9.4.6.1
GROWING RESEARCH ACTIVITIES AND STRATEGIC EXPANSIONS IN OLIGONUCLEOTIDE SYNTHESIS TO AID MARKET
9.4.7
REST OF ASIA PACIFIC
9.5
LATIN AMERICA
9.5.1
LATIN AMERICA: MACROECONOMIC OUTLOOK
9.5.2
BRAZIL
9.5.2.1
AVAILABILITY OF LEADING OLIGO-BASED THERAPIES TO SUPPORT MARKET GROWTH
9.5.3
MEXICO
9.5.3.1
GROWING ADOPTION OF NGS TECHNOLOGY TO DRIVE MARKET
9.5.4
ARGENTINA
9.5.4.1
INCREASING RESEARCH COLLABORATIONS AND GOVERNMENT SUPPORT TO BOOST MARKET
9.5.5
REST OF LATIN AMERICA
9.6
MIDDLE EAST
9.6.1
MIDDLE EAST: MACROECONOMIC OUTLOOK
9.6.2
GCC COUNTRIES
9.6.2.1
SAUDI ARABIA (KSA)
9.6.2.2
UNITED ARAB EMIRATES (UAE)
9.6.2.3
OTHER GCC COUNTRIES
9.6.3
REST OF MIDDLE EAST
9.7
AFRICA
9.7.1
IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
9.7.2
AFRICA: MACROECONOMIC OUTLOOK
10
COMPETITIVE LANDSCAPE
Discover top strategies and market leaders shaping the research, diagnostic, and therapeutic sectors.
331
10.1
INTRODUCTION
10.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3
REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.3.1
REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022−2024
10.3.2
REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022−2024
10.4
MARKET SHARE ANALYSIS
10.4.1
MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
10.4.2
MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024
10.5
COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
10.5.1
STARS
10.5.2
EMERGING LEADERS
10.5.3
PERVASIVE PLAYERS
10.5.4
PARTICIPANTS
10.6
COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024
10.6.1
STARS
10.6.2
EMERGING LEADERS
10.6.3
PERVASIVE PLAYERS
10.6.4
PARTICIPANTS
10.6.5
COMPANY FOOTPRINT:
10.6.5.1
COMPANY FOOTPRINT (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.6.5.2
REGION FOOTPRINT (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.6.5.3
PRODUCT FOOTPRINT (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.6.5.4
APPLICATION FOOTPRINT (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.6.5.5
COMPANY FOOTPRINT (THERAPEUTIC APPLICATIONS)
10.6.5.6
REGION FOOTPRINT (THERAPEUTIC APPLICATIONS)
10.6.5.7
PRODUCT FOOTPRINT (THERAPEUTIC APPLICATIONS)
10.6.5.8
APPLICATION FOOTPRINT (THERAPEUTIC APPLICATIONS)
10.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.7.1
PROGRESSIVE COMPANIES
10.7.2
RESPONSIVE COMPANIES
10.7.3
DYNAMIC COMPANIES
10.7.4
STARTING BLOCKS
10.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
10.7.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
10.8
COMPANY VALUATION & FINANCIAL METRICS
10.8.1
FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.8.2
COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.8.3
FINANCIAL METRICS (THERAPEUTIC APPLICATIONS)
10.8.4
COMPANY VALUATION (THERAPEUTIC APPLICATIONS)
10.9
BRAND/PRODUCT COMPARATIVE ANALYSIS
10.9.1
BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.9.2
BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
10.10
COMPETITIVE SCENARIO
10.10.1
PRODUCT APPROVALS
11
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
360
11.1
KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS)
11.1.1
DANAHER CORPORATION
11.1.1.1
BUSINESS OVERVIEW
11.1.1.2
PRODUCTS OFFERED
11.1.1.3
RECENT DEVELOPMENTS
11.1.1.4
MNM VIEW
11.1.2
THERMO FISHER SCIENTIFIC INC.
11.1.3
MERCK KGAA
11.1.4
LGC LIMITED
11.1.5
EUROFINS SCIENTIFIC
11.1.6
AGILENT TECHNOLOGIES, INC.
11.1.7
KANEKA CORPORATION
11.1.8
MARAVAI LIFESCIENCES
11.1.9
AZENTA US INC.
11.1.10
TWIST BIOSCIENCE
11.1.11
GENSCRIPT
11.2
KEY PLAYERS (THERAPEUTIC APPLICATIONS)
11.2.1
BIOGEN
11.2.2
ALNYLAM PHARMACEUTICALS, INC.
11.2.3
SAREPTA THERAPEUTICS, INC.
11.2.4
ASTRAZENECA
11.2.5
ASTELLAS PHARMA INC.
11.2.6
JAZZ PHARMACEUTICALS PLC
11.2.7
NIPPON SHINYAKU, CO. LTD.
11.2.8
IONIS PHARMACEUTICALS, INC.
11.2.9
NOVARTIS AG
11.3
OTHER PLAYERS
11.3.1
OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
11.3.2
BIOLEGIO B.V.
11.3.3
BIOLYTIC LAB PERFORMANCE, INC.
11.3.4
BIOCOMMA LIMITED
11.3.5
REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.)
11.3.6
BIO-SYNTHESIS, INC.
11.3.7
CREATIVE BIOGENE
11.3.8
REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)
12
APPENDIX
448
12.1
DISCUSSION GUIDE
12.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3
CUSTOMIZATION OPTIONS
12.4
RELATED REPORTS
12.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
TABLE 2
FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016−2025)
TABLE 3
LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 4
APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
TABLE 5
AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024
TABLE 6
AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022-2024
TABLE 7
AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
TABLE 8
AVERAGE SELLING PRICE FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
TABLE 9
INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
TABLE 10
IMPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)
TABLE 11
IMPORT VOLUME FOR HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS)
TABLE 12
EXPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)
TABLE 13
EXPORT VOLUME FOR HS CODE 9027-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020–2024 (TONS)S
TABLE 14
OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS
TABLE 15
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20
OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 21
KEY COMPANIES IMPLEMENTING AI
TABLE 22
US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 23
KEY PRODUCT-RELATED TARIFF: MISCELLANEOUS CHEMICAL PRODUCTS, PHARMACEUTICAL PRODUCTS, ORGANIC CHEMICALS.
TABLE 24
CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
TABLE 25
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 26
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 27
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 28
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33
OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2023–2030 (NUMBER OF VIALS)
TABLE 34
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 35
APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
TABLE 36
ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 37
NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38
EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39
ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42
GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
TABLE 44
SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 45
NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50
GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51
APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS
TABLE 52
OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 53
NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56
LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58
GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 60
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 67
OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 68
NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69
EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70
ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72
MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 75
NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77
ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81
DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 82
NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84
ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86
MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 89
NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91
ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93
MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94
GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 96
NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98
ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101
GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 103
CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 104
NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107
LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108
MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110
PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 111
NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113
ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114
LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115
MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116
GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117
OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 118
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 125
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 132
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 133
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 137
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 138
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 140
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 141
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 146
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 148
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 153
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 155
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 160
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 162
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 163
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 168
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION)
TABLE 170
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 171
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION)
TABLE 175
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 177
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 178
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 179
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 180
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
TABLE 182
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 184
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 187
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 189
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 191
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 192
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 194
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 196
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 198
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 199
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 200
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 201
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 204
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 206
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 207
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 208
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 209
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 210
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 211
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 212
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 213
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 214
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 215
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 216
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 217
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 218
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION)
TABLE 220
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 221
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 223
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 224
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2023–2030 (USD MILLION)
TABLE 225
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 226
OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 227
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 228
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 229
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 230
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 231
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 232
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 233
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 234
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 235
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 236
NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 237
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 238
NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 239
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 240
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 241
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 242
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 243
US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 244
US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 245
US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 246
US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 247
US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 248
US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 249
US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 250
US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 251
CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 252
CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 253
CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 254
CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 255
CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 256
CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 257
CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 258
CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 259
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 260
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 261
EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 262
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 263
EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 264
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 265
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 266
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 267
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 268
GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 269
GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 270
GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 271
GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 272
GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 273
GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 274
GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 275
GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 276
UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 277
UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 278
UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 279
UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 280
UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 281
UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 282
UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 283
UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 284
FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 285
FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 286
FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 287
FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 288
FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 289
FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 290
FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 291
FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 292
ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 293
ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 294
ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 295
ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 296
ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 297
ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 298
ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 299
ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 300
SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 301
SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 302
SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 303
SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 304
SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 305
SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 306
SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 307
SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 308
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 309
REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 310
REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 311
REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 312
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 313
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 314
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 315
REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 316
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 317
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 318
ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 319
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 320
ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 321
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 322
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 323
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 324
ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 325
CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 326
CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 327
CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 328
CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 329
CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 330
CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 331
CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 332
CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 333
JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 334
JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 335
JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 336
JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 337
JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 338
JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 339
JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 340
JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 341
INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 342
INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 343
INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 344
INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 345
INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 346
INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 347
INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 348
INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 349
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 350
AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 351
AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 352
AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 353
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 354
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 355
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 356
AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 357
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 358
SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 359
SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 360
SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 361
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 362
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 363
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 364
SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 365
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 366
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 367
REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 368
REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 369
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 370
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 371
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 372
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 373
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 374
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 375
LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 376
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 377
LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 378
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 379
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 380
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 381
LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 382
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 383
BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 384
BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 385
BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 386
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 387
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 388
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 389
BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 390
MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 391
MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 392
MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 393
MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 394
MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 395
MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 396
MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 397
MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 398
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 399
ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 400
ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 401
ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 402
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 403
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 404
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 405
ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 406
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 407
REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 408
REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 409
REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 410
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 411
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 412
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 413
REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 414
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 415
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 416
MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 417
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 418
MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 419
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 420
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 421
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 422
MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 423
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 424
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 425
GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 426
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 427
GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 428
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 429
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 430
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 431
GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 432
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 433
SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 434
SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 435
SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 436
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 437
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 438
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 439
SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 440
UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 441
UNITED ARAB EMIRATES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 442
UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 443
UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 444
UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 445
UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 446
UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 447
UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 448
OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 449
OTHER GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 450
OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 451
OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 452
OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 453
OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 454
OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 455
OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 456
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 457
REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 458
REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 459
REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 460
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 461
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 462
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 463
REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 464
AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 465
AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 466
AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 467
AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 468
AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 469
AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)
TABLE 470
AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 471
AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 472
STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2025
TABLE 473
STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS), 2022–2025
TABLE 474
OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): DEGREE OF COMPETITION
TABLE 475
OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): DEGREE OF COMPETITION
TABLE 476
OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): REGIONAL FOOTPRINT
TABLE 477
OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): PRODUCT FOOTPRINT
TABLE 478
OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): APPLICATION FOOTPRINT
TABLE 479
OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): REGION FOOTPRINT
TABLE 480
OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): PRODUCT FOOTPRINT
TABLE 481
OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): APPLICATION FOOTPRINT
TABLE 482
DETAILED LIST OF KEY STARTUPS/SMES
TABLE 483
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 484
OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS, JANUARY 2022–MAY 2025
TABLE 485
OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2022-MAY 2025
TABLE 486
OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2022-MAY 2025
TABLE 487
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 488
DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 489
DANAHER CORPORATION: DEALS, JANUARY 2021−MAY 2025
TABLE 490
DANAHER CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 491
DANAHER CORPORATION: OTHER DEVELOPMENTS
TABLE 492
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 493
THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 494
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−MAY 2025
TABLE 495
MERCK KGAA: COMPANY OVERVIEW
TABLE 496
MERCK KGAA: PRODUCTS OFFERED
TABLE 497
MERCK KGAA: DEALS, JANUARY 2021−MAY 2025
TABLE 498
MERCK KGAA: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 499
LGC LIMITED: COMPANY OVERVIEW
TABLE 500
LGC LIMITED: PRODUCTS OFFERED
TABLE 501
LGC LIMITED: DEALS, JANUARY 2021−MAY 2025
TABLE 502
LGC LIMITED: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 503
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 504
EUROFINS SCIENTIFIC: PRODUCTS OFFERED
TABLE 505
EUROFINS SCIENTIFIC: DEALS, JANUARY 2021−MAY 2025
TABLE 506
EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 507
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 508
AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 509
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021−MAY 2025
TABLE 510
AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 511
KANEKA CORPORATION: COMPANY OVERVIEW
TABLE 512
KANEKA CORPORATION: PRODUCTS OFFERED
TABLE 513
KANEKA CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 514
MARAVAI LIFESCIENCES: COMPANY OVERVIEW
TABLE 515
MARAVAI LIFESCIENCES: PRODUCTS OFFERED
TABLE 516
MARAVAI LIFESCIENCES: DEALS, JANUARY 2021−MAY 2025
TABLE 517
MARAVAI LIFESCIENCES: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 518
AZENTA US INC.: COMPANY OVERVIEW
TABLE 519
AZENTA US INC.: PRODUCTS OFFERED
TABLE 520
TWIST BIOSCIENCE: COMPANY OVERVIEW
TABLE 521
TWIST BIOSCIENCE: PRODUCTS OFFERED
TABLE 522
TWIST BIOSCIENCE: DEALS, JANUARY 2021−MAY 2025
TABLE 523
GENSCRIPT: COMPANY OVERVIEW
TABLE 524
GENSCRIPT: PRODUCTS OFFERED
TABLE 525
GENSCRIPT: DEALS, JANUARY 2021−MAY 2025
TABLE 526
GENSCRIPT: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 527
BIOGEN: COMPANY OVERVIEW
TABLE 528
BIOGEN: PRODUCTS OFFERED
TABLE 529
BIOGEN: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
TABLE 530
BIOGEN: DEALS, JANUARY 2021−MAY 2025
TABLE 531
BIOGEN: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 532
ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
TABLE 533
ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
TABLE 534
ALNYLAM PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
TABLE 535
ALNYLAM PHARMACEUTICALS INC.: DEALS, JANUARY 2021−MAY 2025
TABLE 536
SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 537
SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 538
SAREPTA THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
TABLE 539
SAREPTA THERAPEUTICS: EXPANSIONS, JANUARY 2021−MAY 2025
TABLE 540
ASTRAZENECA: COMPANY OVERVIEW
TABLE 541
ASTRAZENECA: PRODUCTS OFFERED
TABLE 542
ASTRAZENECA: DEALS, JANUARY 2021−MAY 2025
TABLE 543
ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
TABLE 544
ASTELLAS PHARMA INC.: COMPANY OVERVIEW
TABLE 545
ASTELLAS PHARMA INC.: PRODUCTS OFFERED
TABLE 546
ASTELLAS PHARMA INC.: DEALS, JANUARY 2021−MAY 2025
TABLE 547
ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
TABLE 548
JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
TABLE 549
JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED
TABLE 550
NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW
TABLE 551
NIPPON SHINYAKU, CO. LTD.: PRODUCTS OFFERED
TABLE 552
NIPPON SHINYAKU, CO. LTD.: DEALS, JANUARY 2021−MAY 2025
TABLE 553
IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
TABLE 554
IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED
TABLE 555
IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
TABLE 556
IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2021−MAY 2025
TABLE 557
NOVARTIS AG: COMPANY OVERVIEW
TABLE 558
NOVARTIS AG: PRODUCTS OFFERED
TABLE 559
NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021−MAY 2025
TABLE 560
NOVARTIS AG: DEALS, JANUARY 2021−MAY 2025
TABLE 561
OLIGOMAKER APS: COMPANY OVERVIEW
TABLE 562
BIOLEGIO B.V.: COMPANY OVERVIEW
TABLE 563
BIOLYTIC LAB PERFORMANCE, INC.: COMPANY OVERVIEW
TABLE 564
BIOCOMMA LIMITED: COMPANY OVERVIEW
TABLE 565
REVVITY: COMPANY OVERVIEW
TABLE 566
BIO-SYNTHESIS, INC.: COMPANY OVERVIEW
TABLE 567
CREATIVE BIOGENE: COMPANY OVERVIEW
TABLE 568
REPROCELL INC.: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION
FIGURE 2
RESEARCH DESIGN
FIGURE 3
BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 4
MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024
FIGURE 5
MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
FIGURE 6
MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2024
FIGURE 7
ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH & DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2024
FIGURE 8
ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2024
FIGURE 9
MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 10
MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 11
CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2025–2030
FIGURE 12
CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET (THERAPEUTIC APPLICATIONS), 2025–2030
FIGURE 13
GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET
FIGURE 14
DATA TRIANGULATION METHODOLOGY
FIGURE 15
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
FIGURE 16
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 17
OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2024−2029 (USD MILLION)
FIGURE 18
GEOGRAPHIC SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET
FIGURE 19
RISING DEMAND FOR SYNTHESIZED OLIGOS FOR DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET
FIGURE 20
THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR MARKET SHARE IN US IN 2O24
FIGURE 21
OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2030
FIGURE 22
THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
FIGURE 23
NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 24
OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25
REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE MANUFACTURERS
FIGURE 26
VALUE CHAIN ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
FIGURE 27
VALUE CHAIN ANALYSIS (THERAPEUTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
FIGURE 28
ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET
FIGURE 29
AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022−2024
FIGURE 30
AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024
FIGURE 31
TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2014–DECEMBER 2024)
FIGURE 32
OLIGONUCLEOTIDE DRUGS PIPELINE, BY DISEASE
FIGURE 33
OLIGONUCLEOTIDE DRUGS PIPELINE, BY PHASE
FIGURE 34
OLIGONUCLEOTIDE DRUGS PIPELINE, BY REGION
FIGURE 35
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
FIGURE 36
STAKEHOLDERS INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS
FIGURE 37
BUYING CRITERIA OF END USERS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS
FIGURE 38
BUYING CRITERIA OF HOSPITALS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS
FIGURE 39
NIH FUNDING FOR OLIGONUCLEOTIDE SYNTHESIS PROJECTS, 2014–2024
FIGURE 40
AI USE CASES
FIGURE 41
NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
FIGURE 42
EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
FIGURE 43
OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2024
FIGURE 44
OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022–2024
FIGURE 45
OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), BY KEY PLAYER, 2024
FIGURE 46
MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS), BY KEY PLAYER, 2024
FIGURE 47
OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
FIGURE 48
OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024
FIGURE 49
OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): COMPANY FOOTPRINT
FIGURE 50
OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): COMPANY FOOTPRINT
FIGURE 51
OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2024
FIGURE 52
EV/EBITDA OF KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS)
FIGURE 53
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS)
FIGURE 54
EV/EBITDA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
FIGURE 55
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
FIGURE 56
BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS)
FIGURE 57
BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
FIGURE 58
DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 59
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 60
MERCK KGAA: COMPANY SNAPSHOT (2024)
FIGURE 61
LGC LIMITED: COMPANY SNAPSHOT (2024)
FIGURE 62
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
FIGURE 63
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 64
KANEKA CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 65
MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2024)
FIGURE 66
AZENTA US INC.: COMPANY SNAPSHOT (2024)
FIGURE 67
TWIST BIOSCIENCE: COMPANY SNAPSHOT (2024)
FIGURE 68
GENSCRIPT: COMPANY SNAPSHOT (2024)
FIGURE 69
BIOGEN: COMPANY SNAPSHOT (2024)
FIGURE 70
ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)
FIGURE 71
SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2024)
FIGURE 72
ASTRAZENECA: COMPANY SNAPSHOT (2024)
FIGURE 73
ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024)
FIGURE 74
JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2024)
FIGURE 75
NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2024)
FIGURE 76
IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)
FIGURE 77
NOVARTIS AG: COMPANY SNAPSHOT (2024)
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global oligonucleotide synthesis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Industry Association of Synthetic Biology (IASB), Biotechnology Innovation Organization (BIO), and Genome Canada. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate & validate the total size of the oligonucleotide synthesis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Oligonucleotide synthesis is the chemical process of creating nucleic acid fragments with specific chemical structures or sequences of varying sizes to form a desired product. These fragments, known as oligonucleotides, have several applications in medical & life science research. They can be used for DNA sequencing and amplification, detecting complementary DNA or RNA through hybridization, creating artificial genes, and introducing targeted genetic mutations.
Oligonucleotides are also used to develop therapeutic drugs. These drugs are produced chemically and have different mechanisms of action, such as interfering with gene expression, blocking the production of harmful proteins, or restoring the function of mutated genes.
Stakeholders
- Pharmaceutical & biotechnology companies
- Hospitals
- Diagnostic laboratories
- Academic researchers and government research organizations
- Private research institutes
- Custom oligonucleotide service providers
- Contract manufacturing organizations (CMOs)
- Oligonucleotide equipment manufacturers
- Contract research organizations (CROs)
- Market research & consulting firms
- Venture capitalists
Report Objectives
- To define, describe, and forecast the global oligonucleotide synthesis market based on the product, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oligonucleotide synthesis market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the oligonucleotide synthesis market.
- To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the oligonucleotide synthesis market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Oligonucleotide Synthesis Market